Related references
Note: Only part of the references are listed.Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study
Theodore M. Brasky et al.
CANCER CAUSES & CONTROL (2010)
Analgesic Use and Sex Steroid Hormone Concentrations in Postmenopausal Women
Margaret A. Gates et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2010)
Use of Aspirin, Other Nonsteroidal Anti-inflammatory Drugs, and Acetaminophen and Risk of Breast Cancer Among Premenopausal Women in the Nurses' Health Study II
A. Heather Eliassen et al.
ARCHIVES OF INTERNAL MEDICINE (2009)
Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression
Jonine D. Figueroa et al.
CANCER CAUSES & CONTROL (2009)
Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial
S. M. Zhang et al.
BRITISH JOURNAL OF CANCER (2008)
Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer
Amanda I. Phipps et al.
CANCER (2008)
Nonsteroidal anti-inflammatory drug use and serum total estradiol in postmenopausal women
Alana G. Hudson et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
Modulation of Breast Cancer Risk by Nonsteroidal Anti-inflammatory Drugs
Louise R. Howe et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Relation of demographic factors, menstrual history, reproduction and medication use to sex hormone levels in postmenopausal women
Anne McTiernan et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study
Gretchen L. Gierach et al.
BREAST CANCER RESEARCH (2008)
Nonsteroidal antiinflammatory drugs and breast cancer risk - The multiethnic cohort
Jasmeet K. Gill et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2007)
Nonsteroidal antlinflammatory drug use and breast cancer risk: Subgroup findings
Victoria A. Kirsh et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2007)
Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD
Lisa Gallicchio et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Differences in risk factors for breast cancer molecular subtypes in a population-based study
Xiaohong R. Yang et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
Inflammation and cancer: How hot is the link?
Bharat B. Aggarwal et al.
BIOCHEMICAL PHARMACOLOGY (2006)
Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB
V. Benoit et al.
ONCOGENE (2006)
Cyclo-oxygenase-2 (COX-2) mRNA expression and hormone receptor status in breast cancer
K. McCarthy et al.
EJSO (2006)
Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma
M. H. Cho et al.
BREAST (2006)
HER-2/neu status is a determinant of mammary aromatase activity in vivo:: Evidence for a cyclooxygenase-2-dependent mechanism
Kotha Subbaramaiah et al.
CANCER RESEARCH (2006)
p53 mutation analysis in breast tumors by a DNA microarray method
M Tennis et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2006)
Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: The case-control surveillance study revisited
YQ Zhang et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2005)
Low-dose aspirin in the primary prevention of cancer the women's health study: A randomized controlled trial
NR Cook et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status
SF Marshall et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer
RW Brueggemeier et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2005)
Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma
L Nakopoulou et al.
PATHOBIOLOGY (2005)
Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2
V Benoit et al.
ONCOGENE (2004)
COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ
GP Boland et al.
BRITISH JOURNAL OF CANCER (2004)
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
TO Nielsen et al.
CLINICAL CANCER RESEARCH (2004)
Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk
MB Terry et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Cyclooxygenase-2 and chemoprevention of breast cancer
GLS Davies
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2003)
Repeated observation of breast tumor subtypes in independent gene expression data sets
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Cyclo-oxygenase-2 (COX-2) mRNA expression correlates with progesterone receptor positivity in human breast cancer
G Singh-Ranger et al.
CURRENT MEDICAL RESEARCH AND OPINION (2003)
p53-mediated induction of Cox-2 counteracts p53-or genotoxic stress-induced apoptosis
JA Han et al.
EMBO JOURNAL (2002)
Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer - Evidence for involvement of AP-1 and PEA3
K Subbaramaiah et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention
G Davies et al.
ANNALS OF ONCOLOGY (2002)
Breast cancer and NSAID use: a meta-analysis
SA Khuder et al.
BRITISH JOURNAL OF CANCER (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
